Key Takeaways
• Treatment.com AI has completed the full acquisition of Rocket Doctor Inc. under a share purchase agreement.
• The transaction includes an initial $7.69 million in shares and up to $6.9 million in milestone-based contingent shares.
• Rocket Doctor’s virtual care model will integrate with Treatment.com’s AI-powered clinical tools like the AI Nurse and GLM.
• Treatment.com has assumed C$627,000 in liabilities and issued incentives to retain Rocket Doctor personnel.
• The acquisition aims to accelerate AI-enabled remote healthcare access across North America.
Treatment.com AI, listed on the Canadian Securities Exchange (CSE: TRUE), is a technology-driven healthcare firm focused on reducing inefficiencies in the medical system through artificial intelligence.
Its flagship product, the Global Library of Medicine (GLM), provides clinical guidance and diagnostic decision support, with over 10,000 expert medical reviews.
Rocket Doctor empowers physicians to establish virtual or hybrid practices using proprietary software and remote diagnostic devices.
The company focuses on delivering care to rural, underserved, and Medicaid populations, addressing barriers like location, cost, and social stigma.
Deal Summary: Terms and Valuation
Under the Definitive Agreement dated February 11, 2025, Treatment.com acquired all outstanding shares of Rocket Doctor Inc.
• Initial Payment: $7,688,640 in Treatment.com shares, priced at $0.65 per share
• Contingent Milestone Shares: Up to $6,902,560 based on 12- and 24-month performance targets
• Escrow Timeline: Shares released in stages between 12 and 32 months
Financial and Operational Impacts
Treatment.com’s financial and operational commitments related to the acquisition include:
• Assumed C$627,000 in Rocket Doctor’s long-term liabilities
• Provided a C$750,000 bridge loan in five installments
• Issued 900,000 stock options and up to 2,747,979 RSUs tied to performance milestones
No changes are planned for Treatment.com’s executive leadership or board of directors. No finder’s fees were involved in the transaction.
Strategic Integration: AI Meets Remote Diagnostics
The acquisition enhances Treatment.com’s ability to integrate AI-powered tools into Rocket Doctor’s virtual care platform. Notably, it creates a live testing environment for products like the company’s conversational AI Nurse application.
“We are excited to now formally welcome the Rocket Doctor team… This will not only help create efficiency and aid the practitioners on the platform, but also provide a proof of concept for future commercial sales of Treatment’s software.” — Dr. Essam Hamza, CEO, Treatment.com AI
Rocket Doctor’s physician-led platform uses AI, wireless diagnostics, and LLMs to support virtual practices and deliver personalized care across North America.
“It’s clear that we are all aligned in building and growing something sustainable and impactful… while leveraging the most advanced technology in this ever evolving AI era.” — Dr. William Cherniak, Co-founder & CEO, Rocket Doctor
Broader Context: Aligning with Industry Trends
The deal reflects an increasing trend in health tech: merging AI-powered decision support with scalable telemedicine infrastructure.
Treatment.com’s GLM platform and upcoming AI Nurse solution support triage, diagnostics, and administrative streamlining for clinical teams.
By combining those tools with Rocket Doctor’s operational model, the companies aim to offer improved care delivery for vulnerable populations while validating the commercial scalability of AI-first virtual health solutions.
Treatment.com AI’s acquisition of Rocket Doctor signifies more than a merger—it marks the evolution of a healthcare model that is intelligent, scalable, and inclusive.
With aligned missions and integrated technologies, the two companies are poised to expand high-quality, AI-supported virtual healthcare across North America.
For more news and insights, visit AI News on our website.
